Month: January 2021

News published on RÚV that Skeljungur´s subsidiary, P/F Magn, is in the process of being sold, is not correct.The article also referred to that the alleged sale is part of Skeljungur´s restructuring. No decision has been made by the company on its restructuring.

Frétt sem birtist á RÚV þess efnis að dótturfélag Skeljungs, P/F Magn, væri komið í söluferli, er ekki rétt.Þá er einnig vísað til þess í fréttinni að meint sala sé hluti af endurskipulagningu Skeljungs. Engar ákvarðanir hafa verið teknar af félaginu um endurskipulagningu þess.

UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (“Merus”, “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced the pricing of an underwritten public offering of 4,848,485 common shares at a public offering price of $24.75 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $120 million. In addition, Merus granted the underwriters a 30-day option to purchase up to an additional 727,272 common shares at the public offering price, less the underwriting discounts and commissions. All of the shares in the offering are to be sold by Merus.The offering is expected...

Press release, Copenhagen 21 January 2021US-based Tealium has developed a standard connector to Danish omnichannel marketing software company Agillic. With the connector, clients using Tealium, a Customer Data Platform (CDP), and Agillic can more easily create and execute highly personalised communication based on data from many disparate sources.With the standard connector, the synergy between the Tealium Customer Data Platform and Agillic enhances the capacity and intelligence of both systems, enabling a more personalised communication, which is recognised as impacting conversion rates and boosting the value of the marketing communication significantly.The standard connector substitutes a custom webhook and enables smoother data exchange between the Tealium CDP and the Agillic Platform. As the CDP collects vital data from many sources,...

ROCKAWAY, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Health Improvement Scotland (“HIS”) has published a Scottish Health Technology Group (“SHTG”) adaptation for NHS Scotland on the use of gammaCore for cluster headache. The SHTG publication is based on guidance produced in 2019 by the U.K. National Institute for Health and Care Excellence (“NICE”), which states that gammaCore, when used alongside standard of care, can reduce the frequency and intensity of cluster headache attacks, leading to significant quality of life benefits for people living with this condition and can save an average of £450 per patient in the first year of treatment through a reduction in acute rescue medication use, and with electroCore offering no-cost...

BOTHELL, Wash., Jan. 21, 2021 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the SARS-CoV-2 virus, hepatitis C viruses and noroviruses, provides the following summary of today’s upcoming presentation by Cocrystal President Sam Lee, Ph.D. at the virtual 3rd Annual reimagine Health Research Symposium, University of Arizona College of Medicine. A live webcast of Dr. Lee’s presentation, titled “Application of Structure-Based Drug Design Platform Technology for Developing Broad Spectrum, COVID-19, Influenza, and HCV Antivirals,” will be available at 9:50 a.m. Pacific time (12:50 p.m. Eastern time) by registering here. Dr. Lee’s presentation...

Patients with stable symptoms of schizophrenia were switched from previous antipsychotic medications with no dose titration to CAPLYTA 42 mg for a 6-week treatment duration, then switched back to previous or another approved antipsychotic.In patients with stable symptoms of schizophrenia, CAPLYTA was well-tolerated with low rates of metabolic and extrapyramidal symptoms (EPS) adverse events; schizophrenia symptoms remained stable and did not worsen from baseline.NEW YORK, Jan. 21, 2021 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the publication of results from the CAPLYTA clinical trial (ITI-007-303) in adult patients with schizophrenia. The article, “Safety...

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated November 9, 2020 to its final short form base shelf prospectus for the Province of Quebec and its amended and restated final short form base shelf prospectus for each of the Provinces of Canada except Quebec, each dated October 27, 2020.VANCOUVER, British Columbia, Jan. 21, 2021 (GLOBE NEWSWIRE) — Westport Fuel Systems Inc. (“Westport Fuel Systems”) (TSX:WPRT / Nasdaq:WPRT) today announced it has agreed to commence a research project with Scania to apply its HPDI 2.0TM fuel system with hydrogen to the latest Scania commercial vehicle engine. Preliminary test results are expected in the second half of 2021.“Our specialty is working with gaseous fuels. Hydrogen use in an internal combustion engine with our HPDI fuel...